Fig. 5.

Comprehensive understanding and inhibitor direction for targeting signaling pathways in preclinical HNC treatment. EGFR epidermal growth factor receptor, EGF epidermal augmentum factor, MET mesenchymal–epithelial transition factor, JAK Janus-activated kinase, STAT signal transducer and activator of transcription, AKT serine/threonine-specific protein kinase, mTOR mammalian target of rapamycin, CDK cyclin-dependent kinase, VEGF vascular endothelial growth factor, mAb monoclonal antibody, RET rearranged during transfection, p phosphorylation